Combination
AssigneeGenesis Pharma SA
InventorGeorge Vogiatzis
Life of this patent
Estimating the term…
Loading patent…
AssigneeGenesis Pharma SA
InventorGeorge Vogiatzis
Estimating the term…
The present invention provides a combination comprising at least two of the following: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist, for instance a combination comprising at least two of (i) exenatide, or a functional derivative or analogue thereof, or a pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue thereof, or a pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof. Said combinations are suitable for cardioprotection and for treating and/or preventing ischemia and/or reperfusion injury. Further aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising said combinations according to the invention, and methods of treatment using the same.
A combination comprising an insulin modulator, wherein the insulin modulator is exenatide or a pharmaceutically acceptable salt thereof, and an aldosterone antagonist, wherein the aldosterone antagonist is potassium canrenoate.
2-11. (canceled)
(canceled)
A pharmaceutical product comprising an insulin modulator, wherein the insulin modulator is exenatide, or a pharmaceutically acceptable salt thereof;
17-33. (canceled)
A method of treating and/or preventing one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for providing cardioprotection against cardiotoxic drugs, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof, the following components:
35-37. (canceled)
44-61. (canceled)
A pharmaceutical product comprising an insulin modulator, wherein the insulin modulator is exenatide, or a functional derivative or analogue, or a pharmaceutically acceptable salt thereof;
Dependencies are inferred from the claim text.